Centuple Global Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 510537,
    "name": "Centuple Global",
    "stock_name": "Centuple Global",
    "full_name": "Centuple Global Ltd",
    "name_url": "stocks-analysis/centuple-global",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "37.00",
    "chg": 0.7,
    "chgp": "1.93%",
    "dir": 1,
    "prev_price": "36.30",
    "mcapval": "21.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531099,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE396H01019",
    "curr_date": "Aug 25, 03:32 PM",
    "curr_time": "15:41 PM",
    "last_traded_at": "Aug 25, 03:32 PM IST",
    "bse_nse_vol": "7.17 k",
    "exc_status": "Active",
    "traded_date": "Aug 25, 2026",
    "traded_date_str": "2026 08 25",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/centuple-global-510537-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Checkpoint Trends Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/checkpoint-trends-ltd-is-rated-sell-4151626",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/CheckpointTrend_mojoScore_4151626.png",
        "date": "2026-08-13 10:11:00",
        "description": "Checkpoint Trends Ltd is rated Sell by MarketsMOJO, with this rating last updated on 17 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "When is the next results date for Checkpoint Trends Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-checkpoint-trends-ltd-4138686",
        "imagepath": "",
        "date": "2026-08-05 23:19:09",
        "description": "The next results date for Checkpoint Trends Ltd is not specified in the information available. However, Centuple Global will declare its results on 13 August 2026. If you need further details about Checkpoint Trends Ltd specifically, please let me know...."
      },
      {
        "title": "Are Checkpoint Trends Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-checkpoint-trends-ltd-latest-results-good-or-bad-4024803",
        "imagepath": "",
        "date": "2026-05-31 19:20:56",
        "description": "Checkpoint Trends Ltd's latest financial results for Q4 FY26 present a complex picture of rapid revenue growth juxtaposed with significant challenges in profitability. The company reported net sales of ₹279.41 crores, reflecting a remarkable year-on-year revenue growth of 111,664% from ₹0.25 crores in Q4 FY25. This surge indicates a dramatic transformation in the company's business operations, suggesting successful scaling efforts in the pharmaceutical trading segment.\n\nHowever, despite this impressive revenue increase, Checkpoint Trends Ltd faced a net loss of ₹0.48 crores in the latest quarter, a stark contrast to the profit of ₹0.06 crores reported in the same quarter last year. The operating margin also turned negative at -0.14%, a significant decline from 36.0% in Q4 FY25. This deterioration in margins raises concerns about the company's ability to convert its top-line growth into bottom-line profitabi..."
      },
      {
        "title": "Centuple Global Q4 FY26: Explosive Revenue Growth Masks Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/centuple-global-q4-fy26-explosive-revenue-growth-masks-profitability-concerns-4024538",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CentupleGlobal_quaterlyResult_4024538.png",
        "date": "2026-05-30 23:49:22",
        "description": "Centuple Global Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹26.00 crores, reported extraordinary revenue growth in Q4 FY26 (Mar'26), though profitability turned sharply negative. The company posted net sales of ₹279.41 crores for the quarter, representing a staggering 111,664.00% year-on-year surge, whilst net profit swung to a loss of ₹0.48 crores from a profit of ₹0.06 crores in the year-ago period. Following the results announcement, the stock traded at ₹46.49, down 67.80% from its 52-week high of ₹144.40."
      }
    ],
    "total": 290,
    "sid": "510537",
    "stock_news_url": "https://www.marketsmojo.com/news/centuple-global-510537"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "18-Aug-2026",
      "details": "Newspaper publication",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors",
      "datetime": "14-Aug-2026",
      "details": "Resignation of statutory auditor",
      "source": "BSE"
    },
    {
      "caption": "Outcome Of Board Meeting",
      "datetime": "13-Aug-2026",
      "details": "Outcome of board meeting",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Checkpoint Trends Ltd is Rated Sell

2026-08-13 10:11:00

Checkpoint Trends Ltd is rated Sell by MarketsMOJO, with this rating last updated on 17 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

When is the next results date for Checkpoint Trends Ltd?

2026-08-05 23:19:09

The next results date for Checkpoint Trends Ltd is not specified in the information available. However, Centuple Global will declare its results on 13 August 2026. If you need further details about Checkpoint Trends Ltd specifically, please let me know....

Read full news article

Are Checkpoint Trends Ltd latest results good or bad?

2026-05-31 19:20:56

Checkpoint Trends Ltd's latest financial results for Q4 FY26 present a complex picture of rapid revenue growth juxtaposed with significant challenges in profitability. The company reported net sales of ₹279.41 crores, reflecting a remarkable year-on-year revenue growth of 111,664% from ₹0.25 crores in Q4 FY25. This surge indicates a dramatic transformation in the company's business operations, suggesting successful scaling efforts in the pharmaceutical trading segment. However, despite this impressive revenue increase, Checkpoint Trends Ltd faced a net loss of ₹0.48 crores in the latest quarter, a stark contrast to the profit of ₹0.06 crores reported in the same quarter last year. The operating margin also turned negative at -0.14%, a significant decline from 36.0% in Q4 FY25. This deterioration in margins raises concerns about the company's ability to convert its top-line growth into bottom-line profitabi...

Read full news article

Centuple Global Q4 FY26: Explosive Revenue Growth Masks Profitability Concerns

2026-05-30 23:49:22

Centuple Global Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹26.00 crores, reported extraordinary revenue growth in Q4 FY26 (Mar'26), though profitability turned sharply negative. The company posted net sales of ₹279.41 crores for the quarter, representing a staggering 111,664.00% year-on-year surge, whilst net profit swung to a loss of ₹0.48 crores from a profit of ₹0.06 crores in the year-ago period. Following the results announcement, the stock traded at ₹46.49, down 67.80% from its 52-week high of ₹144.40.

Read full news article

View All News